228 related articles for article (PubMed ID: 17075122)
41. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
42. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
Ramlau R; Gervais R; Krzakowski M; von Pawel J; Kaukel E; Abratt RP; Dharan B; Grotzinger KM; Ross G; Dane G; Shepherd FA
J Clin Oncol; 2006 Jun; 24(18):2800-7. PubMed ID: 16682727
[TBL] [Abstract][Full Text] [Related]
43. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
Gebbia V; Gridelli C; Verusio C; Frontini L; Aitini E; Daniele B; Gamucci T; Mancuso G; Di Maio M; Gallo C; Perrone F; Morabito A
Lung Cancer; 2009 Feb; 63(2):251-8. PubMed ID: 18632181
[TBL] [Abstract][Full Text] [Related]
44. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
45. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Lilenbaum R; Wang X; Gu L; Kirshner J; Lerro K; Vokes E
J Clin Oncol; 2009 Sep; 27(27):4487-91. PubMed ID: 19704058
[TBL] [Abstract][Full Text] [Related]
46. Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Karavasilis V; Kosmidis P; Syrigos KN; Mavropoulou P; Dimopoulos MA; Kotoula V; Pectasides D; Boukovinas I; Klouvas G; Kalogera-Fountzila A; Papandreou CN; Fountzilas G; Briasoulis E
Anticancer Res; 2014 Oct; 34(10):5649-55. PubMed ID: 25275069
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
Eager RM; Cunningham CC; Senzer N; Richards DA; Raju RN; Jones B; Uprichard M; Nemunaitis J
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):464-72. PubMed ID: 19501491
[TBL] [Abstract][Full Text] [Related]
48. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Hoang T; Campbell TC; Zhang C; Kim K; Kolesar JM; Oettel KR; Blank JH; Robinson EG; Ahuja HG; Kirschling RJ; Johnson PH; Huie MS; Wims ME; Larson MM; Hernan HR; Traynor AM
Invest New Drugs; 2014 Feb; 32(1):195-9. PubMed ID: 23728919
[TBL] [Abstract][Full Text] [Related]
49. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Levy B; Spira A; Becker D; Evans T; Schnadig I; Camidge DR; Bauman JE; Hausman D; Walker L; Nemunaitis J; Rudin CM; Halmos B; Bowles DW
J Thorac Oncol; 2014 Jul; 9(7):1031-1035. PubMed ID: 24926548
[TBL] [Abstract][Full Text] [Related]
50. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Lara PN; Chansky K; Davies AM; Franklin WA; Gumerlock PH; Guaglianone PP; Atkins JN; Farneth N; Mack PC; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Nov; 1(9):996-1001. PubMed ID: 17409985
[TBL] [Abstract][Full Text] [Related]
51. Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Juan Ó; Aparisi F; Sánchez-Hernández A; Muñoz-Langa J; Esquerdo G; García-Sánchez J; López A; Garde J; Giner V
Clin Lung Cancer; 2015 May; 16(3):193-9. PubMed ID: 25547902
[TBL] [Abstract][Full Text] [Related]
52. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
53. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
Wang J; Li K; Sun T; Zhang MJ; Li WL; Yao Q; Liu W; Ding CM; He ZY; Mao WD; Wang HM; Zhang Y; Zhou XL
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222
[TBL] [Abstract][Full Text] [Related]
54. Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Cortinovis D; Bidoli P; Cullurà D; Lorusso V; Ardizzoia A; Amoroso V; Bandera M; Aitini E; Fusi A; Zilembo N; Radula D; Bajetta E
J Thorac Oncol; 2008 Apr; 3(4):405-11. PubMed ID: 18379360
[TBL] [Abstract][Full Text] [Related]
55. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
Ross HJ; Hart LL; Swanson PM; Rarick MU; Figlin RA; Jacobs AD; McCune DE; Rosenberg AH; Baron AD; Grove LE; Thorn MD; Miller DM; Drachman JG; Rudin CM
Lung Cancer; 2006 Oct; 54(1):69-77. PubMed ID: 16934909
[TBL] [Abstract][Full Text] [Related]
56. Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.
Gridelli C; Chella A; Valmadre G; Allegrini G; Brighenti M; Bidoli P; Rossi A; Maione P; Migliorino MR; Ricciardi S; DE Marinis F
Anticancer Res; 2016 Dec; 36(12):6535-6540. PubMed ID: 27919979
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J
Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159
[TBL] [Abstract][Full Text] [Related]
58. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
Camps C; Massuti B; Jiménez A; Maestu I; Gómez RG; Isla D; González JL; Almenar D; Blasco A; Rosell R; Carrato A; Viñolas N; Batista N; Girón CG; Galán A; López M; Blanco R; Provencio M; Diz P; Felip E;
Ann Oncol; 2006 Mar; 17(3):467-72. PubMed ID: 16371411
[TBL] [Abstract][Full Text] [Related]
59. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
Kraft AS; Garrett-Mayer E; Wahlquist AE; Golshayan A; Chen CS; Butler W; Bearden J; Lilly M
Cancer Biol Ther; 2011 Jul; 12(2):119-24. PubMed ID: 21532336
[TBL] [Abstract][Full Text] [Related]
60. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Neukirchen J; Meier A; Rohrbeck A; Garcia-Pardillos G; Steidl U; Fenk R; Haas R; Kronenwett R; Rohr UP
Cancer Gene Ther; 2007 Apr; 14(4):431-9. PubMed ID: 17235352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
